Treatment of Neuro-Behçet's disease


KÜRTÜNCÜ M., ALTUNRENDE B., Akman G.

Neuro-Behçet's Disease: Pathogenesis, Clinical Aspects, Treatment, Springer International Publishing Ag, ss.123-149, 2021

  • Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/978-3-030-55273-2_12
  • Yayınevi: Springer International Publishing Ag
  • Sayfa Sayıları: ss.123-149
  • Anahtar Kelimeler: Adalimumab, Anakinra, Azathioprine, Canakinumab, Cyclophosphamide, Etanercept, Infliximab, Mycophenolate mofetil, Neuro-Behçet's disease, Tocilizumab, Treatment
  • Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

There are no randomized trials on the treatment of neuro-Behçet's disease (NBD). Therefore, management is mainly based on studies performed on patients with systemic involvements or case studies. The management of NBD can be summarized as acute treatment and maintenance treatment. The acute treatment consists of high-dose intravenous steroids, followed by an oral taper. An escalation treatment strategy is employed for the maintenance treatment that includes first-line oral immunosuppressants such as azathioprine and mycophenolate mofetil. Cyclophosphamide and anti-TNF-α monoclonal antibodies can be used in refractory cases as second-line treatments. An increasing body of evidence suggests the use of anti-IL-6 and IL-1 monoclonal antibodies for patients with progressive or relapsing disease course on second-line agents.